Viewing Study NCT02625961


Ignite Creation Date: 2025-12-24 @ 1:06 PM
Ignite Modification Date: 2026-01-28 @ 5:17 PM
Study NCT ID: NCT02625961
Status: COMPLETED
Last Update Posted: 2025-11-21
First Post: 2015-12-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module